Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Numab Therapeutics AG

www.numab.com

Latest From Numab Therapeutics AG

Asia Deal Watch: Takeda Licenses Curadev STING Agonist To Further Its IO Ambitions

The Japanese pharma, continuing to bolster its pipeline after buying Shire, is partnering with Skyhawk in neurodegenerative diseases under another new deal. Also, Purdue cites shifting business priorities for a decision to end Eisai collaboration on sleep disorder drug.

Deals Commercial

Deal Watch: Oncternal Goes Public Via Reverse Merger With GTx

All-stock transaction combines privately held Oncternal with GTx, which had been considering its strategic alternatives. Biogen acquires gene therapy biotech Nightstar, MaxCyte and Kite expand their CAR-T partnership.

Deals Business Strategies

Ono Bulks Up MAb R&D With Second Swiss Biotech Deal

Human-derived monoclonal antibodies targeted against neurodegenerative diseases is the subject of a deal between Japan's Ono Pharmaceutical and Zurich-based biotech Neurimmune.

Deals Neurology

Deal Watch: Novartis Signs Deals In Migraine & Diabetes

Novartis will invest in the Calgary-based Parvus and collaborate on a Navacim candidate for type 1 diabetes. Japan's Sawai moves into the US market by acquiring Upsher-Smith's generics business, while Denovo acquires a suspended depression candidate from AMRI for its personalized development approach.

Deals M & A
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
    • Large Molecule
      • Antibodies
    • Transgenics
  • Pharmaceuticals
  • Therapeutic Areas
  • Immune Disorders
  • Respiratory, Pulmonary
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Switzerland
  • Parent & Subsidiaries
  • Numab Therapeutics AG
  • Senior Management
  • David Urech, PhD, CEO
    Roland Helfenstein, CFO
    Oliver Middendorp, PhD, CBO
    Peter Lichtlen, MD, PhD, CMO
    Sebastian Meyer, COO
  • Contact Info
  • Numab Therapeutics AG
    Einsiedlerstrasse 34
    Wädenswil, CH-8820
    Switzerland
Advertisement
Advertisement
UsernamePublicRestriction

Register